Compare · ISPC vs TECH
ISPC vs TECH
Side-by-side comparison of iSpecimen Inc. (ISPC) and Bio-Techne Corp (TECH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ISPC focuses on Biotechnology: Commercial Physical & Biological Resarch, while TECH focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- TECH is the larger of the two at $11.44B, about 2978.3x ISPC ($3.8M).
- TECH has been more active in the news (19 items in the past 4 weeks vs 7 for ISPC).
- TECH has more recent analyst coverage (25 ratings vs 2 for ISPC).
- Company
- iSpecimen Inc.
- Bio-Techne Corp
- Price
- -
- -
- Market cap
- $3.8M
- $11.44B
- 1M return
- -
- +0.41%
- 1Y return
- -
- +18.55%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 19
- Recent ratings
- 2
- 25
Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Latest ISPC
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Regulation FD Disclosure, Financial Statements and Exhibits
- iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products
- iSpecimen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form PRE 14A filed by iSpecimen Inc.
- iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent
- SEC Form DEFR14A filed by iSpecimen Inc.
- SEC Form PRER14A filed by iSpecimen Inc.
- SEC Form 8-K filed by iSpecimen Inc.
- iSpecimen Supports Hospital Validation of New Chemistry Analyzer
Latest TECH
- SEC Form 10-Q filed by Bio-Techne Corp
- Amendment: SEC Form SCHEDULE 13G/A filed by Bio-Techne Corp
- Bio-Techne Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BIO-TECHNE DECLARES DIVIDEND
- Chief Executive Officer Kelderman Kim covered exercise/tax liability with 2,385 shares, decreasing direct ownership by 3% to 80,509 units (SEC Form 4)
- CFO Hippel James converted options into 11,545 shares and covered exercise/tax liability with 5,096 shares, increasing direct ownership by 4% to 176,720 units (SEC Form 4)
- Amendment: CFO Hippel James converted options into 9,980 shares and covered exercise/tax liability with 4,423 shares, increasing direct ownership by 3% to 170,271 units (SEC Form 4)
- Amendment: PRESIDENT, PROTEIN SCIENCES Geist William converted options into 6,547 shares and covered exercise/tax liability with 2,019 shares, increasing direct ownership by 22% to 25,031 units (SEC Form 4)
- Amendment: Chief Executive Officer Kelderman Kim converted options into 21,736 shares and covered exercise/tax liability with 10,955 shares, increasing direct ownership by 15% to 82,894 units (SEC Form 4)
- Amendment: SVP - General Counsel Bohnen Shane converted options into 4,420 shares and covered exercise/tax liability with 1,366 shares, increasing direct ownership by 42% to 10,407 units (SEC Form 4)